(135) also conducted a similar clinical study (NCT01662869) and found that onartuzumab combined with first-line oxaliplatin did not significantly improve clinical prognosis in GC patients with c-Met immunohistochemistry of 2+ and 3+. The gene discussed is MET; the disease is gastric cancer.